Biotechnology company Valitacell has announced a collaboration with life sciences group Solentim to help identify biological candidates earlier and to accelerate the development of breakthrough medicines.
medicines discovery
The companies aim to create a streamlined, automated platform which synergises precise cell manipulations, attribute-rich profiling of clones and earlier decision making. Valitacell’s will combine its in-line analytical profiling technologies and data driven/machine learning approach with Solentim’s innovative image-driven liquid handling and cell measurement technology.
"This collaboration combines our expertise in both biotherapeutics and emergent cellular therapy, and will optimise the process of drug discovery. We look forward to working in partnership with Solentim as we continue to discover and develop life-saving medicines that improve patients’ lives," said Dr Terry McWade, CEO of Valitacell.
Dr Ian Taylor, chief commercial officer of Solentim, added: “We are delighted to be collaborating with Valitacell – this combination of technologies will provide a further component to our unique integrated solution for accelerating stable cell line development workflows. It will provide significant benefits for richer clone information and earlier decision-making on the best candidates to progress."